Bioorganic and Medicinal Chemistry Letters p. 2307 - 2312 (1997)
Update date:2022-07-29
Topics:
Reiter, Lawrence A.
Melvin Jr., Lawrence S.
Crean, Geraldine L.
Showell, Henry J.
Koch, Kevin
Biggers, Michael S.
Cheng, John B.
Breslow, Robbin
Conklyn, Maryrose J.
Farrell, Cathy A.
Hada, William A.
Laird, Ellen R.
Martin, John J.
Miller, G. Todd
Pillar, Joanne S.
The SAR of a series of 7-chromanylacetic acids has been investigated with the aim of identifying potent and selective LTB4 receptor antagonists. We found optimal activity in derivatives with α,α-disubstitution on the acetic acid and a C-4 hydroxy group and a C-3 lipophilic group on the chromane ring. CP-105696 (43), which contains a 4-phenylbenzyl C-3 substituent, was selected for development.
View MoreShenyang Mole pharmaceutical Technology Development Co.,Ltd
Contact:+86-24-31204918/13889278616
Address:No.44, wanliutang road, shenhe District of Shenyang
Changzhou Screw International Trading Co., Ltd.
Contact:13906149256,18001495888
Address:Jiangsu，Jintanqu
website:http://www.sigmaaldrich.com
Contact:800 558-9160
Address:Industriestrasse 25CH-9471 Buchs SGSwitzerland
Nanjing Chemipioneer Pharma&Tech Co.,Ltd
website:http://www.chemipioneer.com.cn
Contact:+86-25-52685700
Address:Room 305，A Block，Biological-Medicine Building，Business Start-up Center，Xin-ke 1st Road, High-tech development zone，Nanjing city，Jiangsu Province, China
Shenzhen Sungening Medicine Co., Ltd
Contact:+86-871-65110906
Address:Room702, Building 2, 365 Dianchi Road, Kunming, Yunnan Province, P.R. China
Doi:10.1016/S0040-4020(97)10046-1
(1997)Doi:10.1007/BF00601117
()Doi:10.1002/jhet.5570340541
(1997)Doi:10.1021/om9707026
(1997)Doi:10.1016/S0040-4039(97)10283-0
(1997)Doi:10.1016/S0022-328X(99)00029-7
(1999)
